[Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
D015250:Aclarubicin; D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009279:Naphthacenes / Q000008:administration & dosage
D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine; D003630:Daunorubicin